Skip to main content
BrainCited

Omega-3 Fatty Acids (DHA/EPA) pour Cerebrovascular Health

B

DHA supports vascular endothelial function and may help reduce neuroinflammation. In CAD patients, 3.36 g/day supplementation was associated with slowed cognitive aging equivalent to approximately 2.5 years.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Domega\u002D3\u002Ddha\u002Depa\u0026condition\u003Dcerebrovascular\u002Dhealth'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

En conclusion

DHA supports vascular endothelial function and may help reduce neuroinflammation. In CAD patients, 3.36 g/day supplementation was associated with slowed cognitive aging equivalent to approximately 2.5 years.

Key Study Findings

Review
The Clinical Implications of Ashwagandha (Withania somnifera L.) with a Special Reference to Side Effects-A …
Dose: None vs: None Outcome: None Effet: None None

Population: narrative review of ashwagandha clinical trials and basic research (1994-present)

Other 10 weeks
Ginkgo biloba Extract GBE50 ameliorates cerebrovascular dysfunction and cognitive impairment in a mouse model of …
Dose: None vs: Untreated APP/PS1 mice Outcome: Cognitive performance in behavioral tests Effet: None None

Population: APP/PS1 transgenic Alzheimer's disease mouse model

Review
Herbal Medicines in Autism Spectrum Disorder: Therapeutic Potential, Plant Components, and Dosage Guidelines.
Dose: None vs: None Outcome: ASD symptom management Effet: None None

Population: Children with autism spectrum disorder

Cohort Study n=215624
Neuroticism, omega-3 fatty acids, and risk of incident dementia.
Dose: None vs: None Outcome: Incident all-cause dementia Effet: None <0.05 (Bonferroni)

Population: Dementia-free UK Biobank participants aged 40-69

preclinical animal/in vitro study
Ashwagandha (Withania somnifera (L.) dunal) root extract containing withanolide a alleviates depression-like behavior in mice …
Dose: 60 and 100 mg/kg (mice); 100 and 200 µg/mL (HT-22 cells); withanolide A 1.56 and 3.12 µg/mL vs: Placebo Effet: None None
Other 26 weeks
Systems biology modelling based evaluation of omega-3 formulation in managing cardiovascular and cerebrovascular risk.
Dose: EPA 180mg + DHA 120mg vs: Simulated disease population baseline Outcome: Lipid biomarker changes (in silico model) Effet: 14.7% TG reduction, 22.38% HDL increase None

Population: Simulated CVD disease population (in silico study)

Key Statistics

12

Études

2000

Participants

Positive

B

Note

Referenced Papers

Nutrients 2025 2 citations
Acta pharmaceutica Sinica. … 2024 33 citations
La Revue du … 2024
Nature reviews. Disease … 2021 163 citations
The Senior care … 2021 2 citations
Journal of ethnopharmacology 2020 85 citations
Current neurology and … 2019 11 citations
Sleep medicine 2017 95 citations
Current treatment options … 2017 56 citations
Clinical therapeutics 2016 328 citations
Journal of psychosocial … 2011 26 citations
Journal of Alzheimer's … 2010 110 citations
The Practitioner 2010
The Cochrane database … 2003 263 citations
The Medical clinics … 2002 59 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Posologies couramment utilisées

general:
1,000-2,000 mg combined DHA/EPA per day
cognitivesupport:
1,000-1,700 mg/day (optimal dose-response curve)

Limite supérieure : 3,000 mg/day combined DHA/EPA (FDA GRAS)

Posologies étudiées dans la recherche

Posologie Durée Effet N
None -- Positive --
None 10 weeks Positive --
None -- Positive --
None -- Positive 215624
60 and 100 mg/kg (mice); 100 and 200 µg/mL (HT-22 cells); withanolide A 1.56 and 3.12 µg/mL -- Positive --
EPA 180mg + DHA 120mg 26 weeks Positive --
None -- Mixed --
None -- Mixed --

Moment optimal de prise : With meals containing fat for better absorption

Safety & Side Effects

Effets indésirables signalés

  • Fishy aftertaste or burping
  • Mild gastrointestinal discomfort
  • Potential increased bleeding time at very high doses
  • May lower blood pressure slightly

Interactions connues

  • Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
  • Blood pressure medications (additive hypotensive effect)
  • Orlistat (may reduce omega-3 absorption)

Apport maximal tolérable : 3,000 mg/day combined DHA/EPA (FDA GRAS)

Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.Consultez toujours votre professionnel de santé avant de commencer tout complément alimentaire.

Frequently Asked Questions

Does Omega-3 Fatty Acids (DHA/EPA) help with Cerebrovascular Health?
Based on 12 studies with 2,000 participants, there is moderate evidence from clinical studies that Omega-3 Fatty Acids (DHA/EPA) may support Cerebrovascular Health management. Our evidence grade is B (Good Evidence).
How much Omega-3 Fatty Acids (DHA/EPA) should I take for Cerebrovascular Health?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined DHA/EPA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (DHA/EPA)?
Reported side effects may include Fishy aftertaste or burping, Mild gastrointestinal discomfort, Potential increased bleeding time at very high doses, May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (DHA/EPA) and Cerebrovascular Health?
We rate the evidence as Grade B (Good Evidence). This rating is based on 12 peer-reviewed studies with 2,000 total participants. The overall direction of effect is positive.

Related Evidence

Avertissement FDA: Ces déclarations n'ont pas été évaluées par la Food and Drug Administration. Les produits et informations sur ce site ne sont pas destinés à diagnostiquer, traiter, guérir ou prévenir quelque maladie que ce soit. Les notes de preuve présentées sont basées sur notre analyse de la recherche publiée et évaluée par des pairs et ne constituent pas un avis médical. Consultez toujours votre professionnel de santé avant de commencer tout régime de compléments alimentaires.